HomeCompareSYN vs VICI

SYN vs VICI: Dividend Comparison 2026

SYN yields 196.08% · VICI yields 6.52%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 VICI wins by $889.7K in total portfolio value· pulled ahead in Year 7
10 years
SYN
SYN
● Live price
196.08%
Share price
$1.02
Annual div
$2.00
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$76.5K
Annual income
$74.42
Full SYN calculator →
VICI
VICI Properties Inc.
● Live price
6.52%
Share price
$27.32
Annual div
$1.78
5Y div CAGR
44.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$966.2K
Annual income
$607,376.13
Full VICI calculator →

Portfolio growth — SYN vs VICI

📍 VICI pulled ahead of the other in Year 7

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSYNVICI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SYN + VICI cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SYN pays
VICI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SYN
Annual income on $10K today (after 15% tax)
$16,666.67/yr
After 10yr DRIP, annual income (after tax)
$63.26/yr
VICI
Annual income on $10K today (after 15% tax)
$554.58/yr
After 10yr DRIP, annual income (after tax)
$516,269.71/yr
At 15% tax rate, VICI beats the other by $516,206.45/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SYN + VICI for your $10,000?

SYN: 50%VICI: 50%
100% VICI50/50100% SYN
Portfolio after 10yr
$521.4K
Annual income
$303,725.27/yr
Blended yield
58.25%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on VICI right now

SYN
Analyst Ratings
5
Buy
2
Hold
Consensus: Buy
Altman Z
-14.5
Piotroski
2/9
VICI
Analyst Ratings
20
Buy
6
Hold
Consensus: Buy
Price Target
$31.60
+15.7% upside vs current
Range: $30.00 — $33.00
Altman Z
1.4
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SYN buys
0
VICI buys
0
No recent congressional trades found for SYN or VICI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSYNVICI
Forward yield196.08%6.52%
Annual dividend / share$2.00$1.78
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%44.3%
Portfolio after 10y$76.5K$966.2K
Annual income after 10y$74.42$607,376.13
Total dividends collected$34.4K$926.2K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyBuy

Year-by-year: SYN vs VICI ($10,000, DRIP)

YearSYN PortfolioSYN Income/yrVICI PortfolioVICI Income/yrGap
1$20,504$9,803.92$11,361$941.49+$9.1KSYN
2$31,333$9,393.40$13,320$1,481.32+$18.0KSYN
3$40,234$6,707.62$16,284$2,405.01+$23.9KSYN
4$47,075$4,024.82$21,040$4,071.78+$26.0KSYN
5$52,570$2,200.55$29,209$7,285.49+$23.4KSYN
6$57,399$1,148.35$44,443$14,006.51+$13.0KSYN
7← crossover$62,003$585.89$75,822$29,512.55$13.8KVICI
8$66,638$295.74$148,733$69,726.75$82.1KVICI
9$71,452$148.53$344,394$189,413.75$272.9KVICI
10$76,528$74.42$966,234$607,376.13$889.7KVICI

SYN vs VICI: Complete Analysis 2026

SYNStock

Synthetic Biologics, Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics; SYN-005 for the prevention and treatment of pertussis; and VCN-11 to treat cancer. It has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Synthetic Biologics, Inc. is headquartered in Rockville, Maryland.

Full SYN Calculator →

VICIREIT

VICI Properties is an experiential real estate investment trust that owns one of the largest portfolios of market-leading gaming, hospitality and entertainment destinations, including the world-renowned Caesars Palace. VICI Properties' national, geographically diverse portfolio consists of 29 gaming facilities comprising over 48 million square feet and features approximately 19,200 hotel rooms and more than 200 restaurants, bars and nightclubs. Its properties are leased to industry leading gaming and hospitality operators, including Caesars Entertainment, Inc., Century Casinos Inc., Hard Rock International, JACK Entertainment and Penn National Gaming, Inc. VICI Properties also owns four championship golf courses and 34 acres of undeveloped land adjacent to the Las Vegas Strip. VICI Properties' strategy is to create the nation's highest quality and most productive experiential real estate portfolio.

Full VICI Calculator →
📬

Get this SYN vs VICI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SYN vs SCHDSYN vs JEPISYN vs OSYN vs KOSYN vs MAINSYN vs NNNSYN vs EPRTSYN vs ADC

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.